These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 37371096)

  • 1. Ferroptosis-Mediated Cell Death Induced by NCX4040, The Non-Steroidal Nitric Oxide Donor, in Human Colorectal Cancer Cells: Implications in Therapy.
    Sinha BK; Bortner CD; Jarmusch AK; Tokar EJ; Murphy C; Wu X; Winter H; Cannon RE
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Cell Death Induced by Erastin in Human Ovarian Tumor Cells.
    Sinha BK; Murphy C; Brown SM; Silver BB; Tokar EJ; Bortner CD
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid Peroxidation-Dependent Cell Death Regulated by GPx4 and Ferroptosis.
    Imai H; Matsuoka M; Kumagai T; Sakamoto T; Koumura T
    Curr Top Microbiol Immunol; 2017; 403():143-170. PubMed ID: 28204974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms of Cytotoxicity of NCX4040, the Non-Steroidal Anti-Inflammatory NO-Donor, in Human Ovarian Cancer Cells.
    Sinha BK; Tokar EJ; Bortner CD
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Expression Profiling Elucidates Cellular Responses to NCX4040 in Human Ovarian Tumor Cells: Implications in the Mechanisms of Action of NCX4040.
    Sinha BK; Tokar EJ; Li J; Bushel PR
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer.
    Sui X; Zhang R; Liu S; Duan T; Zhai L; Zhang M; Han X; Xiang Y; Huang X; Lin H; Xie T
    Front Pharmacol; 2018; 9():1371. PubMed ID: 30524291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RSL3 and Erastin differentially regulate redox signaling to promote Smac mimetic-induced cell death.
    Dächert J; Schoeneberger H; Rohde K; Fulda S
    Oncotarget; 2016 Sep; 7(39):63779-63792. PubMed ID: 27588473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.
    Codenotti S; Poli M; Asperti M; Zizioli D; Marampon F; Fanzani A
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1717-1730. PubMed ID: 29971532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resibufogenin inhibited colorectal cancer cell growth and tumorigenesis through triggering ferroptosis and ROS production mediated by GPX4 inactivation.
    Shen LD; Qi WH; Bai JJ; Zuo CY; Bai DL; Gao WD; Zong XL; Hao TT; Ma Y; Cao GC
    Anat Rec (Hoboken); 2021 Feb; 304(2):313-322. PubMed ID: 31961485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [MACC1 knockdown enhances RSL3-induced ferroptosis in human colorectal cancer cells by inhibiting GPX4 expression].
    Sun S; Huang X; Li G; Zhang C; Lu Z; Zhang W; Li Z; Yang Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 Jan; 44(1):173-178. PubMed ID: 38293989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SRSF9 enhances the sensitivity of colorectal cancer to erastin-induced ferroptosis by reducing glutathione peroxidase 4 expression.
    Wang R; Su Q; Yin H; Wu D; Lv C; Yan Z
    Int J Biochem Cell Biol; 2021 May; 134():105948. PubMed ID: 33609745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of HT22 neuronal cells against chemically-induced ferroptosis by catechol estrogens: protein disulfide isomerase as a mechanistic target.
    Huang X; Hou MJ; Zhu BT
    Sci Rep; 2024 Oct; 14(1):23988. PubMed ID: 39402104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-545 promotes colorectal cancer by inhibiting transferring in the non-normal ferroptosis signaling.
    Zheng S; Hu L; Song Q; Shan Y; Yin G; Zhu H; Kong W; Zhou C
    Aging (Albany NY); 2021 Dec; 13(24):26137-26147. PubMed ID: 34954694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
    Yang J; Mo J; Dai J; Ye C; Cen W; Zheng X; Jiang L; Ye L
    Cell Death Dis; 2021 Nov; 12(11):1079. PubMed ID: 34775496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death.
    Probst L; Dächert J; Schenk B; Fulda S
    Biochem Pharmacol; 2017 Sep; 140():41-52. PubMed ID: 28595877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPX4 overexpressed non-small cell lung cancer cells are sensitive to RSL3-induced ferroptosis.
    Kim JW; Min DW; Kim D; Kim J; Kim MJ; Lim H; Lee JY
    Sci Rep; 2023 May; 13(1):8872. PubMed ID: 37258589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of ferroptosis by photodynamic therapy and enhancement of antitumor effect with ferroptosis inducers.
    Kojima Y; Tanaka M; Sasaki M; Ozeki K; Shimura T; Kubota E; Kataoka H
    J Gastroenterol; 2024 Feb; 59(2):81-94. PubMed ID: 37947872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 19. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets.
    Wang Y; Zhang Z; Sun W; Zhang J; Xu Q; Zhou X; Mao L
    Biomed Pharmacother; 2022 Sep; 153():113524. PubMed ID: 36076606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.